I

n a sensational lawsuit, a former Mallinckrodt (MNK) employee claims that she was fired for repeatedly warning the drug maker about a host of allegedly illegal activities designed to boost sales of a key drug.

Those practices included running a “sham” patient assistance program and refusing to provide payers with clinical data that would be used for making coverage decisions. Moreover, executives were allegedly unaware of the ingredients in the best-selling Achtar drug, which is used to treat infantile spasms and often prescribed for more than a dozen other maladies.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.